Shows reduced final height in children with CML, suggesting early treatment may hinder growth.
= 0.60). In one of the longest follow-up cohorts of children with CML reported to date, imatinib resulted in growth deceleration, particularly when initiated before the onset of pubertal growth spurt. Despite catch-up growth during adolescence, final height z-scores remained reduced at skeletal maturity.
No takes yet. Share an insight, caveat, or question.
Sadanand et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: